profit from every $100 of sales.
$0$100
DaVita
$174.07-5.14% today
+40.8% in 1 year
1-year low $103.871-year high $240.96
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
You pay $14.66 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What DaVita sold, what it kept, and what it did with the cash.
Sales went from $11.6 billion in 2022 to $13.6 billion in 2025, with $747 million of profit last year.
SalesProfit
DaVita handed back more cash to shareholders than it generated last year.
Buybacks $1.8B
Free cash flow 2025$1.3B
Bought back its own shares$1.8B
Paid as dividends$0
Cash vs. debt$676M vs. $12.9B
DaVita vs. similar companies
DaVita grows in the middle of these 5 and is priced in the middle for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| DaVita | 14.7× · Cheap | ||
 Tenet Healthcare | 16.2× · Fair price | ||
 Solventum | 9.7× · Cheap | ||
 Encompass Health | 24.4× · Fair price | ||
 Fresenius Medical Care AG & Co. KGaA | 10.4× · Cheap |
AI analysis
An AI analyst reads DaVita's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 11,551 | 11,619 | 11,610 | 12,140 | 12,816 | 13,643 | |
| – | – | 3,400 | 3,820 | 4,217 | 4,400 | |
| 1,695 | 1,797 | 1,313 | 1,601 | 1,955 | 2,011 | |
| 2,218 | 2,453 | 2,056 | 2,321 | 2,725 | 2,642 | |
| 774 | 978 | 560 | 692 | 936 | 747 | |
| 6.31 | 8.90 | 5.85 | 7.42 | 10.73 | 9.84 | |
| – | – | 29.3% | 31.5% | 32.9% | 32.2% | |
| 14.7% | 15.5% | 11.3% | 13.2% | 15.3% | 14.7% | |
| 6.7% | 8.4% | 4.8% | 5.7% | 7.3% | 5.5% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 16,989 | 17,121 | 16,928 | 16,894 | 17,285 | 17,480 |
| Cash | 325 | 462 | 244 | 380 | 795 | 676 |
| Total debt | 11,194 | 8,908 | 11,822 | 11,116 | 12,067 | 12,874 |
| Total liabilities | 14,092 | 14,751 | 14,703 | 14,150 | 15,194 | 16,322 |
| 1,384 | 756 | 712 | 1,056 | 121 | -651 | |
| 123 | 110 | 96 | 93 | 87 | 76 | |
| 10.1% | 14.6% | 8.3% | 10.2% | 13.0% | 12.5% | |
| 55.9% | 129.5% | 78.7% | 65.5% | 773.1% | -114.7% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,979 | 1,931 | 1,565 | 2,059 | 2,022 | 1,887 | |
| 675 | 641 | 603 | 568 | 555 | 576 | |
| 1,304 | 1,289 | 961 | 1,491 | 1,467 | 1,311 | |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,458 | 1,539 | 802 | 272 | 1,386 | 1,793 | |
| 91 | 102 | 95 | 112 | 103 | 140 |
Valuation
- 14.7×
- 12.3×
- 1.58
- -17.7×
- 0.8×
- 8.4×
- 8.8×
- 12.0%
- 6.8%
- 0.0%
Profitability
- 32.2%
- 14.7%
- 5.5%
- 19.5%
- 10.7%
- 6.1%
- -133.1%
- 4.5%
- 14.2%
- –
Growth
- +3.4%
- +9.3%
- −10.6%
- –
- −4.9%
Financial health
- 4.6×
- -17.50
- 75.6%
- 3.7×
- 1.42
- 1.37
- 0.79
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 27%of 952
Top 36%of 883
Top 20%of 576
Bottom 22%of 870
Top 5%of 985
What analysts expect
- Average price target
- $168.67
- Range
- $158.00 – $190.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | 2.87 | 2.41 | +19.1% |
| Feb 2, 2026 | 3.40 | 3.24 | +4.9% |
| Oct 29, 2025 | 2.51 | 3.17 | −20.8% |
| Aug 5, 2025 | 2.95 | 2.70 | +9.3% |
| May 12, 2025 | 2.00 | 1.95 | +2.6% |
| Feb 13, 2025 | 2.24 | 2.14 | +4.7% |
| Oct 29, 2024 | 2.59 | 2.72 | −4.8% |
| Aug 6, 2024 | 2.50 | 2.54 | −1.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
50No pass
Benjamin Graham
72Pass
Philip Fisher
51No pass
Peter Lynch
39No pass
Joel Greenblatt
43No pass
Charlie Munger
46No pass
Terry Smith
45No pass
Questions about DaVita
Is DaVita a good stock to buy?
A business with weak numbers, and the price looks low. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the DaVita AI analysis
What does DaVita do?
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It is in Medical - Care Facilities, based in Denver, CO, United States, with 78,000 employees.
Does DaVita pay a dividend?
No. DaVita does not pay a dividend at the moment; in 2025 it returned $1.79 billion to shareholders by buying back its own shares.
Is DaVita stock halal?
No. DaVita does not pass our halal screen: its debt is 118% of its market value, at or above the 33% limit. How we check
How has DaVita stock done over the past year?
Up 40.8% over the past twelve months, to $174.07. It traded between $103.87 and $240.96 and is 27.8% below its high.
Who are DaVita's competitors?
The largest listed companies in the same industry are Tenet Healthcare, Solventum, Encompass Health and Fresenius Medical Care AG & Co. KGaA. The peers table on this page compares their profit, growth and price with DaVita's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.